Calls for papers
-
Following soon after United Therapeutics’ announcement that the FDA had cleared an IND for a Phase 2 trial of the company’s treprostinil SMI in patients with PH-COPD, the company has announced an IND clearance for… Read more . . .
-
Phase 2a trial of AerTherapeutics’ nebulized fexlamose failed to meet primary or secondary endpoints
Aer Therapeutics has announced that a Phase 2a trial of fexlamose (AER-01) inhalation solution in patients with moderate-to-severe COPD failed to meet primary or secondary endpoints and also demonstrated an increased incidence of adverse events… Read more . . .
-
Blue Lake Biotechnology announced that it has received a $5 million grant from the Gates Foundation to support the addition of younger children to a Phase 1/2a clinical trial of its BLB201 nasal vaccine against… Read more . . .
-
This year’s Drug Delivery to the Lungs (DDL) meeting will introduce a few innovations to its regular program of scientific lectures, industry and poster exhibitions, including the new DDL Incubator. DDL 2026 will take place… Read more . . .
-
Aptar Pharma announced that it has acquired Pulmotree, the developer of the Kolibri mesh nebulizer, which it refers to as a non-propellant liquid inhaler. The Kolibri nebulizer is a breath-activated, connected device that provides real-time… Read more . . .
-
AptarGroup has announced that Virginie Maes, who is currently VP of Healthcare Flexibles at Amcor, will join the company as President of Aptar Pharma as of January 1, 2027. Maes joined Amcor in 2016; her prior… Read more . . .
-
Israeli biotech Nano24 announced that a Phase 2b trial of nebulized EXO-CD24 exosomes in patients with acute respiratory distress syndrome met its primary endpoint, with 85% of patients who received EXO-CD24 having an SpO2/FiO2 >315… Read more . . .
-
According to United Therapeutics, the FDA has cleared the company’s IND for the 16-week Phase 2 SUMMIT trial of treprostinil SMI in patients with pulmonary hypertension associated with COPD, which is expected to enroll approximately… Read more . . .
-
Aptar Pharma’s LuerVax single-use nasal vaccine delivery device is now CE marked, the company announced. An optional accessory that allows for division of the vaccine so that half of the dose can be sprayed into… Read more . . .
-
According to Liquidia, the company has reached a settlement with United Therapeutics to end all litigation related to patent infringement by Liquidia’s Yutrepia treprostinil DPI. A United States District Court judge recently ruled that Yutrepia… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA